Loading...
ROCO
6576
Market cap386mUSD
Oct 08, Last price  
78.20TWD
1D
-1.01%
1Q
-5.90%
Jan 2017
18.09%
IPO
-14.78%
Name

Foresee Pharmaceuticals Co Ltd

Chart & performance

D1W1MN
ROCO:6576 chart
P/E
—
P/S
28.57
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.61%
Rev. gr., 5y
13.35%
Revenues
431m
+3.01%
75,198,000230,439,000226,029,000301,506,000195,038,000418,689,000431,274,000
Net income
-883m
L-18.31%
-487,212,000-510,713,000-569,267,000-472,638,000-1,036,302,000-1,081,072,000-883,151,000
CFO
-842m
L-28.24%
-447,818,000-674,796,000-213,334,000-233,224,000-887,555,000-1,173,750,000-842,227,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclinical and clinical first-in-class New Chemical Entity (NCE) programs targeting rare and severe disease areas with high unmet needs. Its product portfolio includes late and early-stage programs, with its lead product CAMCEVI® used for the treatment of advanced prostate cancer.

Key people

Meng Kung Chan
Chief Financial Officer, Corporate Governance Officer · since 2023
Wenjin Yang
Chief Scientific Officer · since 2022
Benjamin Chien
Chairman of the Board, General Manager · since 2021
Bassem Elmankabadi
Senior Deputy General Manager-Clinical Development · since 2023
Yuhua Li
Chief Technology Officer · since 2024
William Miller
Deputy General Manager-Regulatory Affairs · since 2021
Jagdish Parasrampuria
Senior Deputy General Manager-CMC & Manufacturing · since 2020
Mathieu Boudreau
Chief Business Officer · since 2017
Ruby Chen
Accounting Manager · since 2024
Yisheng Lee
Chief Medical Officer, Director · since 2024
Jia-Long Lee
Director · since 2015
Jeff Wang
Director · since 2016
Vincent Yen
Director · since 2013
Kun-hong Lai
Independent Director · since 2018
Wen-Chi Lee
Independent Director · since 2016
Ben Liu
Independent Director · since 2023
Fu-Shiow Yin
Independent Director · since 2016
URL
https://www.foreseepharma.com/
IPO date
Apr 12, 2016
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT